Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.

British journal of cancer - 1 Aug 2024

Budczies Jan, Romanovsky Eva, Kirchner Martina, Neumann Olaf, Blasi Miriam, Schnorbach Johannes, Shah Rajiv, Bozorgmehr Farastuk, Savai Rajkumar, Stiewe Thorsten, Peters Solange, Schirmacher Peter, Thomas Michael, Kazdal Daniel, Christopoulos Petros, Stenzinger Albrecht

Abstract excerpt

BACKGROUND: Predictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential of activating KRAS and pathogenic TP53 mutations to provide additional predictive information. METHODS: The study cohort included 713 consecutive immunotherapy patients with advanced lung adenocarcinomas, negative for actionable genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 38866964
DOI: 10.1038/s41416-024-02746-z
PMCID: PMC11300455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.PMID 38866964Read ↗

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.Semantic proximity Read ↗

Differential Benefit of Immune Checkpoint Blockade by<i>KRAS</i>Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish CohortSemantic proximity Read ↗

Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

STK11/KEAP1 co-mutations in SMARCA4-mutant advanced non-small cell lung cancer: genetic characteristics and impact on immunotherapy efficacySemantic proximity Read ↗

Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer.Semantic proximity Read ↗

Co-occurring genomic alterations and immunotherapy efficacy in NSCLCSemantic proximity Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.Semantic proximity Read ↗

Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A One Institution Retrospective AnalysisSemantic proximity Read ↗

Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancerSemantic proximity Read ↗

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.Semantic proximity Read ↗

Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.